Manganese based MR contrast agents: Formulation and clinical applications

Elizaveta Chabanova; Vibeke Berg Løgager; Jakob Møllenbach Møller; Henrik Segelcke Thomsen

Manganese based MR contrast agents: Formulation and clinical applications

Elizaveta Chabanova, Vibeke Berg Løgager, Jakob Møllenbach Møller, Henrik Segelcke Thomsen

8 Citations (Scopus)

Abstract

This paper discusses the development and clinical applications of positive manganese based MR contrast agents, including both intravenous (i.v.) and oral formulations. The i.v. formulation is a manganese-dipyridoxyl diphosphate chelate which is commercially available; whereas the oral formulation is a mixture of MnCl2, alanine and Vitamin D3, which is currently under clinical trials. The compositions, preclinical studies and pharmacokinetics of both formulations are discussed. The main reported clinical difference between the two formulations is that i.v. administration exposes all the organs, whereas oral ingestion exposes only the enterohepatic circulation. Manganese based MR contrast agents are particularly suitable for detection of focal liver lesions due to their uptake by the mitochondria rich hepatocytes, and biliary delineation due to their biliary excretion; it can provide useful information in diffuse liver lesions. Further, the i.v. formulation can be used for focal pancreatic lesions.

Original language	Danish
Journal	The Open Drug Safety Journal
Volume	2
Pages (from-to)	29-38
Number of pages	10
Publication status	Published - 2011

Cite this

@article{e558394365ba450094b2b86a26798075,

title = "Manganese based MR contrast agents: Formulation and clinical applications",

abstract = "This paper discusses the development and clinical applications of positive manganese based MR contrast agents, including both intravenous (i.v.) and oral formulations. The i.v. formulation is a manganese-dipyridoxyl diphosphate chelate which is commercially available; whereas the oral formulation is a mixture of MnCl2, alanine and Vitamin D3, which is currently under clinical trials. The compositions, preclinical studies and pharmacokinetics of both formulations are discussed. The main reported clinical difference between the two formulations is that i.v. administration exposes all the organs, whereas oral ingestion exposes only the enterohepatic circulation. Manganese based MR contrast agents are particularly suitable for detection of focal liver lesions due to their uptake by the mitochondria rich hepatocytes, and biliary delineation due to their biliary excretion; it can provide useful information in diffuse liver lesions. Further, the i.v. formulation can be used for focal pancreatic lesions.",

author = "Elizaveta Chabanova and L{\o}gager, {Vibeke Berg} and M{\o}ller, {Jakob M{\o}llenbach} and Thomsen, {Henrik Segelcke}",

year = "2011",

language = "Dansk",

volume = "2",

pages = "29--38",

journal = "The Open Drug Safety Journal",

issn = "1876-8180",

publisher = "Bentham Open",

}

TY - JOUR

T1 - Manganese based MR contrast agents: Formulation and clinical applications

AU - Chabanova, Elizaveta

AU - Løgager, Vibeke Berg

AU - Møller, Jakob Møllenbach

AU - Thomsen, Henrik Segelcke

PY - 2011

Y1 - 2011

N2 - This paper discusses the development and clinical applications of positive manganese based MR contrast agents, including both intravenous (i.v.) and oral formulations. The i.v. formulation is a manganese-dipyridoxyl diphosphate chelate which is commercially available; whereas the oral formulation is a mixture of MnCl2, alanine and Vitamin D3, which is currently under clinical trials. The compositions, preclinical studies and pharmacokinetics of both formulations are discussed. The main reported clinical difference between the two formulations is that i.v. administration exposes all the organs, whereas oral ingestion exposes only the enterohepatic circulation. Manganese based MR contrast agents are particularly suitable for detection of focal liver lesions due to their uptake by the mitochondria rich hepatocytes, and biliary delineation due to their biliary excretion; it can provide useful information in diffuse liver lesions. Further, the i.v. formulation can be used for focal pancreatic lesions.

AB - This paper discusses the development and clinical applications of positive manganese based MR contrast agents, including both intravenous (i.v.) and oral formulations. The i.v. formulation is a manganese-dipyridoxyl diphosphate chelate which is commercially available; whereas the oral formulation is a mixture of MnCl2, alanine and Vitamin D3, which is currently under clinical trials. The compositions, preclinical studies and pharmacokinetics of both formulations are discussed. The main reported clinical difference between the two formulations is that i.v. administration exposes all the organs, whereas oral ingestion exposes only the enterohepatic circulation. Manganese based MR contrast agents are particularly suitable for detection of focal liver lesions due to their uptake by the mitochondria rich hepatocytes, and biliary delineation due to their biliary excretion; it can provide useful information in diffuse liver lesions. Further, the i.v. formulation can be used for focal pancreatic lesions.

M3 - Tidsskriftartikel

SN - 1876-8180

VL - 2

SP - 29

EP - 38

JO - The Open Drug Safety Journal

JF - The Open Drug Safety Journal

ER -